Psychedelics ETF Climbs on 23% Surge in Compass Pathways Shares
AdvisorShares Psychedelics ETF’s 8.62% exposure to Compass Pathways saw premarket gains as Compass reported a 3.8-point MADRS reduction in its Phase 3 COMP006 25 mg arm (p<0.001). Shares surged over 23% premarket as 39% of participants achieved ≥25% symptom reduction, fueling discussions for a Q4 2026 NDA submission.
1. ETF Exposure to Compass Pathways
AdvisorShares Psychedelics ETF holds an 8.62% position in Compass Pathways, making it one of the fund’s largest exposures within its psychedelic-focused portfolio. This concentration means significant share moves in Compass have a notable effect on the ETF’s net asset value and overall performance.
2. Compass Phase 3 Trial Results
Compass Pathways announced that its Phase 3 COMP006 trial met its primary endpoint, reporting a mean Montgomery-Åsberg Depression Rating Scale reduction of 3.8 points in the 25 mg arm (p<0.001) and a 39% responder rate. The formulation was generally well-tolerated, with most adverse events classified as mild or moderate.
3. Impact on PSIL Outlook
Following the trial success, Compass shares surged over 23% in premarket trading, driving gains in PSIL through its substantial stake. The positive data strengthens the case for a New Drug Application submission in Q4 2026 and may attract new investor interest in both Compass and the Psychedelics ETF.